Peter B. Bach, MD

@peterbachmd

Health Outcomes and Health Policy Pulmonary and ICU Physician, Policy analyst, Writer. Viewpoints are my own.

New York, NY
Vrijeme pridruživanja: travanj 2011.

Medijski sadržaj

  1. 29. sij

    And here is a sample of 3 policies we describe and how they alter the Reward Box shape and thus the risk and reward of developing particular types of drugs:

    Prikaži ovu nit
  2. 28. sij

    these are really narrow areas of focus, but yes this point is often overlooked. But here is a graph that puts this in perspective for Neupogen, often touted as a 'success' story of biosimilar entry.

  3. 10. pro 2019.

    Policy goal: post exclusivity prices to marginal cost. Crude overlay of longer trend on chart (ht ). Reminder launch is still multiples of marginal cost. Enormous oppty cost compared to price regulation AND no patient benefit.

  4. 10. pro 2019.
    Odgovor korisniku/ci

    Where is the gif for goal post moving? Oh I found it. The goal is marginal economic cost for all biologics post exclusivity. Not happening in these days.

  5. 9. pro 2019.
    Odgovor korisnicima

    trends in Diabetes incidence (percentages and counts) from CDC, 1958-2015. Seems a pity to abandon trying to treat this condition, ranked as #7 killer in the US (83,000 per year).

  6. 27. stu 2019.

    I am sure will tweet about this too, and use both more and better gif's. And it will be:

    Prikaži ovu nit
  7. 27. stu 2019.

    Focusing on 2019 top 10 drugs in each category, savings if we had negotiated down to UK prices would have been just shy of $27B for one year across all payers. H.R.3 would save more. Abt $350B in Medicare alone over a decade, the Grassley-Wyden bill about $130B over a decade.

    Prikaži ovu nit
  8. 26. stu 2019.

    Top/bottom ranked states life expectancy has w/in state diff from top to bottom quartiles of 8-10 yrs. In other words, an unimaginable number of lost years of life and not plausible we can drug our way to ameliorating this problem, particularly with our focus on rare conditions.

  9. 26. stu 2019.

    One of the charts I showed with the uptick in 'deaths of despair' (not my term, I think Case and Deaton coined it). I don't think the best first answer to this is that we need new therapies for these problems, figuring out why we lost ground and getting it back probably is).

  10. 23. stu 2019.

    Juul age verification system nicely summarized. Does this even count as making an effort?

  11. 22. stu 2019.

    This is the problem with using percentages . NIH funding to DFCI over past 10 years appears in nominal dollars to be increasing. So I think 'filling the gap' is not a good summary, but it is a much more favorable narrative.

  12. 21. stu 2019.

    Looking forward to speaking at , will cover innovation incentives and that they work, maybe too well. The gains are not distributed across society even though the costs are.

  13. 29. lis 2019.

    Swag from : Someone in marketing seems to have misunderstood the term "combination therapy." (actually anti-abuse packaging - H/T)

  14. 24. lis 2019.

    Very flattered to have the chance to speak at about the challenges currently posed by high drug prices (with some solutions thrown in).

  15. 23. ruj 2019.

    Looking forward to discussing drug pricing following the surprise appearance by Wendell Primus of office.

  16. 23. ruj 2019.

    Must-read report from on the yawning gap in drug prices between US and other countries, step-by-step empirically debunks the explanations, calls for negotiation. Some killer graphs like this one on MS drugs

  17. 12. ruj 2019.
    Odgovor korisnicima
  18. 10. ruj 2019.

    Wait, what? They call this result “positive”. HR of 0.99 and p = .95?

  19. 4. ruj 2019.

    GIF laden thread through the tall grass of various Part D restructuring proposals.

  20. 26. kol 2019.

    Remember referring to its subsidiary Avexis in the recent FDA data “issue” with Zolgensma? Time tested tactics perfected by . They did it again today in the opiate settlement with OK. Cc ⁦

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·